title: Macrocyclic Cu(II)tetraanhydroaminobenzaldehyde complex--antiproliferative activity in vitro and in vivo.
abstract: The macrocyclic Cu(II)-tetraanhydroaminobenzaldehyde complex Cu(TAAB)C12 induces various cytotoxic effects in the dependence on a cell line, concentration and time of exposition. The highest complex concentration of 914 nmol/l induces degeneration of certain part of the HeLa cells population after 24 hours of cultivation. The concentration of 183 nmol/l causes a delayed cytotoxic effect on HeLa and HepG2 cells. After 24 hours of culturing 15.4-28.4% of cell population proliferated but after 48 and 72 hours 2.0-42.3% of the cell population degenerated. The cytotoxic effect on V79 cells is directly dependent on the actual concentration and time of the complex influence. The cytotoxic concentrations of Cu(TAAB)Cl2 induce an integrity damage of cytoplasmatic membrane and two phase unbalanced growth. Cu(TAAB)Cl2 possesses an antileukemic activity which at the dose of 10 mg/kg of body weight is not accompanied by side toxic effects on mice.
authors.affiliation: Department of Biochemistry and Microbiology, Faculty of Chemical Technology, Slovak University of Technology, Bratislava.
authors.forename: S
authors.initials: S
authors.lastname: Jantová
authors.forename: Z
authors.initials: Z
authors.lastname: Duracková
authors.forename: L
authors.initials: L
authors.lastname: Novotný
authors.forename: M
authors.initials: M
authors.lastname: Urbancíková
authors.forename: I
authors.initials: I
authors.lastname: Dovinová
authors.forename: J
authors.initials: J
authors.lastname: Labuda
authors.forename: L
authors.initials: L
authors.lastname: Wsolová
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001547:Benzaldehydes / Q000737:chemistry*; D006528:Carcinoma, Hepatocellular / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D002462:Cell Membrane / Q000187:drug effects; D006224:Cricetinae; D003412:Cricetulus; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004354:Drug Screening Assays, Antitumor; D005347:Fibroblasts / Q000737:chemistry / Q000187:drug effects; D006131:Growth Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006367:HeLa Cells / Q000737:chemistry / Q000187:drug effects; D006801:Humans; D007939:Leukemia L1210 / Q000188:drug therapy*; D008113:Liver Neoplasms / Q000473:pathology; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D009363:Neoplasm Proteins / Q000032:analysis; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D011506:Proteins / Q000032:analysis; D014407:Tumor Cells, Cultured / Q000737:chemistry / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D001547:Benzaldehydes; C116754:Cu(II)tetranhydroaminobenzaldehyde; D006131:Growth Inhibitors; D009363:Neoplasm Proteins; D009942:Organometallic Compounds; D011506:Proteins; C042450:copper tetrabenzo(b,f,j,n)-1,5,9,13-tetraazacyclohexadecine